Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Brenzavvy (bexagliflozin) and Farxiga (dapagliflozin) are both medications in the sodium-glucose cotransporter 2 (SGLT2) inhibitor class used to treat Type 2 diabetes. They help lower blood sugar levels by preventing sugar from being reabsorbed in the kidneys, causing it to be removed through urine. However, they have some differences. Brenzavvy is only approved for Type 2 diabetes, while Farxiga is also approved to reduce the risk of hospitalization and death in adults with heart failure and chronic kidney disease. Brenzavvy is taken as a 20 mg tablet once daily, whereas Farxiga is typically started at 5 mg and can be increased to 10 mg daily. Farxiga is available in both brand-name and generic forms, making it potentially more affordable. Common side effects for both include urinary tract infections, yeast infections, and increased urination. Both medications can interact with other diabetes medications, increasing the risk of low blood sugar.
Brenzavvy (bexagliflozin)
Farxiga (dapagliflozin)
Brenzavvy (bexagliflozin)
Farxiga (dapagliflozin)
Summary of Brenzavvy vs. Farxiga
Summary for SGLT2 inhibitor
Prescription only
Brenzavvy (bexagliflozin) is a newly-approved medication that's used along with a healthy diet and exercise to lower blood sugar levels in people with Type 2 diabetes. This medication is a tablet that's taken by mouth every day in the morning. The most common side effects of Brenzavvy (bexagliflozin) are more frequent urinary tract infections (UTIs) and urinating more than usual since it works to remove blood sugar from your body through the urine.
Summary for SGLT2 inhibitor
Prescription only
Farxiga, the brand name for dapagliflozin, is used together with a nutritious diet and exercise plan to lower blood sugar levels in people 10 years and older with Type 2 diabetes. It can also help lower the risk of serious complications, hospitalization, and death in certain adults with heart failure or chronic kidney disease (CKD). Farxiga (dapagliflozin) belongs to the drug class called sodium-glucose cotransporter 2 (SGLT2) inhibitors. It's taken by mouth once a day. Some side effects include yeast infections, urinating more often, and weight loss.
Indications of Brenzavvy vs. Farxiga
Indications for
•Type 2 diabetes
Indications for
•Type 2 diabetes (in addition to diet and exercise) in people age 10 and over
•Lowering the risk of hospitalization for heart failure in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in people with heart failure
•Lowering the risk of worsening kidney problems, hospitalization for heart failure, and death due to heart problems in adults with chronic kidney disease (CKD)
Pros and Cons of Brenzavvy vs. Farxiga
Pros and Const for SGLT2 inhibitor
Pros
•Taken only once a day
•Can use alone or together with other diabetes medications